source
- Sarepta CEO Sees Path to Stronger DMD Trials Amid 2025 Elevidys SetbacksSarepta Therapeutics’ newly appointed chief executive Michael Severino, after a 90‑day assessment period, outlined a plan to restore the company’s leadership in the Duchenne muscular dystrophy mark…
- Moderna posts first profit in two years, driven by Covid-19 vaccine sales, as it refocuses on cancer vaccinesModerna reported a modest profit for the quarter, marking its first earnings surplus in two years. The turnaround was driven primarily by continued sales of its international Covid-19 vaccine portf…